NDAINTRAVENOUSSOLUTION
Approved
Oct 2025
Lifecycle
Launch
Competitive Pressure
0/100
Clinical Trials
2
Data completeness
5/8 — Partial
ROCURONIUM BROMIDE (rocuronium bromide) by B. Braun is duration. Approved for anesthesia, neuromuscular blockade, surgery and 1 more indications. First approved in 2025.
Drug data last refreshed 21h ago
Mechanism of Action
duration. It acts by competing for cholinergic receptors at the motor end-plate. This action is antagonized by acetylcholinesterase inhibitors, such as neostigmine and edrophonium.
Indications (4)
Worked on ROCURONIUM BROMIDE at B. Braun? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.